Listed

TherapeuticsMD, Inc.: Form 10-K for the period ended Dec 31, 2018

Filed with the SEC on Feb 27, 2019 and accepted by EDGAR at Feb 26, 2019, 18:45 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-10-01 to 2018-12-31$5.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue12 months2018-01-01 to 2018-12-31$16.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue12 months2018-01-01 to 2018-12-31$2.7mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2018-10-01 to 2018-12-31$4.1mus-gaap:GrossProfit
Gross profit12 months2018-01-01 to 2018-12-31$13.4mus-gaap:GrossProfit
Research and development12 months2018-01-01 to 2018-12-31$27.3mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2018-01-01 to 2018-12-31$116.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2018-01-01 to 2018-12-31−$130.2mus-gaap:OperatingIncomeLoss
Net income3 months2018-10-01 to 2018-12-31−$39.4mus-gaap:NetIncomeLoss
Net income12 months2018-01-01 to 2018-12-31−$132.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-10-01 to 2018-12-31−$0.17us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS12 months2018-01-01 to 2018-12-31−$0.59us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2018-01-01 to 2018-12-31−$106.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2018-01-01 to 2018-12-31$217.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-12-31$161.6mus-gaap:Cash
Current assetsAt period end2018-12-31$186.8mus-gaap:AssetsCurrent
Total assetsAt period end2018-12-31$212.0mus-gaap:Assets
Current liabilitiesAt period end2018-12-31$41.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-12-31$114.5mus-gaap:Liabilities
Long-term debtAt period end2018-12-31$73.4mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2018-12-31$97.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001387131-19-001471. Last ingested by Listed: Nov 14, 2026, 19:24 ET. Listed shows no prices and gives no investment advice.